Weekly Digest – September 2025 Weekly Digest – September 2025 01 September 2025: Zai Lab announces approval of TIVDAK for patients with recurrent or metastatic cervical cancer in Hong Kong Zai Lab announced that the Hong Kong Department of Health […]
Weekly Digest – September 2025 Weekly Digest – September 2025 02 September 2025: Health Canada approves ELAHERE for certain types of platinum resistant ovarian cancers Health Canada has approved ELAHERE (mirvetuximab soravtansine), an antibody-drug conjugate, for adult patients with folate […]
Weekly Digest – September 2025 Weekly Digest – September 2025 02 September 2025: Avenzo Therapeutics announces FDA clearance of Investigational New Drug application for AVZO-103, a potential best-in-class Nectin4/TROP2 bispecific antibody-drug conjugate Avenzo Therapeutics received FDA clearance of its IND […]
Weekly Digest – September 2025 Weekly Digest – September 2025 3 September 2025: Radiance Biopharma signs exclusive license for ‘first in class’ c-Met/EGFR targeted Nano antibody ADC Radiance Biopharma signed an exclusive license agreement with Novatim Immune Therapeutics for global […]
Weekly Digest – September 2025 Weekly Digest – September 2025 3 September 2025: OBI Pharma and AP Biosciences sign technology collaboration agreement to develop next-generation ADC OBI Pharma entered into a Material Transfer and Technology Development Agreement with AP Biosciences […]
Weekly Digest – September 2025 Weekly Digest – September 2025 02 September 2025: Twist Bioscience collaborates with Synthetic Design Lab Twist Bioscience announced a collaboration with Synthetic Design Lab (SDL) to develop novel antibody-drug conjugates (ADCs) for cancer Twist will […]
